Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 1999 Jul-Aug;19(4A):2657-9.

Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.

Author information

1
Department of Urology, RWTH Aachen, Germany.

Abstract

INTRODUCTION:

Transforming growth factor-beta 1 (TGF-beta 1) is found to be most markedly elevated in prostate cancer tissue. We determined the concentration of serum TGF-beta 1 in patients with cancer of the prostate (CaP), and correlated them to tumour stage and serum PSA.

METHODS:

Serum TFG-beta 1 levels and serum PSA levels were determined in 80 patients with untreated CaP (Group I: pT1-3pNoMo: n = 58; Group II: T1-3pN + Mo: n = 6; Group III: T1-4NxM+: n = 16). Patients with histologically confirmed BPH (n = 50) served as controls.

RESULTS:

Median TGF-beta 1 levels were not different in CaP- and in BPH-patients (32.86 ng/ml and 35.15 ng/ml respectively; p > 0.05). Furthermore there was no increase in TGF-beta 1 concentrations with advancing tumour stage (Group I: 32.86 ng/ml; Group II: 34.3 ng/ml; Group III: 33.44 (ng/ml; p > 0.05). No correlation with PSA levels could be established (Spearman r = -0.19; p = 0.05).

CONCLUSION:

TGF-beta 1 was found to be non-discriminative between BPH and CaP. Furthermore no TGF-beta 1 increase could be observed with advancing tumour stage in patients with CaP.

PMID:
10470214
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center